D. Goldstein

发表

Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

P. Murawa, K. Ding, W. Parulekar, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study

K. Kinzler, P. Gibbs, M. Christie, 2018, Gut.

Genetic associations of fatigue and other symptoms following breast cancer treatment: A prospective study

M. Friedlander, D. Goldstein, F. Boyle, 2020, Brain, behavior, & immunity - health.

Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.

John R. Mackey, Fiona Campbell, David Goldstein, 2014, Journal of the National Cancer Institute.

Alcohol, signaling, and ECM turnover.

C. Meyer, S. Dooley, Nadja M Meindl-Beinker, 2010, Alcoholism, clinical and experimental research.

Desmoplastic Reaction in Pancreatic Cancer: Role of Pancreatic Stellate Cells

J S Wilson, H. Friess, N. Merrett, 2004, Pancreas.

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

David Goldstein, Manuel Hidalgo, Thomas Ervin, 2013, The New England journal of medicine.

Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial.

David Goldstein, Florence Huguet, Franck Bonnetain, 2016, JAMA.

Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localised pancreatic cancer.

K. Kinzler, B. Vogelstein, P. Gibbs, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

New molecular and immunotherapeutic approaches in biliary cancer

D. Goldstein, C. Lemech, J. Valle, 2017, ESMO Open.

Post-cancer fatigue is not associated with immune activation or altered cytokine production.

M. Friedlander, D. Goldstein, N. Wilcken, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Fatigue states after cancer treatment occur both in association with, and independent of, mood disorder: a longitudinal study

I. Hickie, M. Friedlander, D. Goldstein, 2006, BMC Cancer.

Fatigue and psychological distress--exploring the relationship in women treated for breast cancer.

I. Hickie, D. Goldstein, T. Davenport, 2004, European journal of cancer.

Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility.

M. Friedlander, D. Goldstein, M. Kiernan, 2011, The oncologist.

Are Australian oncology health professionals burning out? A view from the trenches.

D. Goldstein, V. Hansen, A. Girgis, 2009, European journal of cancer.

Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer.

D. V. Von Hoff, D. Goldstein, M. Renschler, 2014, The New England journal of medicine.

A randomized controlled trial of a standardized educational intervention for patients with cancer pain.

M. Stockler, E. Briganti, P. Butow, 2010, Journal of pain and symptom management.

Taxane-induced peripheral neuropathy: differences in patient report and objective assessment

D. Goldstein, M. Kiernan, F. Boyle, 2020, Supportive Care in Cancer.

Role of pancreatic stellate cells in chemoresistance in pancreatic cancer

D. Goldstein, M. Kavallaris, P. Phillips, 2014, Front. Physiol..

Australasian Gastrointestinal Trials Group (AGITG) and Trans-Tasman Radiation Oncology Group (TROG) Guidelines for Pancreatic Stereotactic Body Radiation Therapy (SBRT).

K. Goodman, L. Holloway, Mark T Lee, 2019, Practical radiation oncology.

Corneal dendritic cells and the subbasal nerve plexus following neurotoxic treatment with oxaliplatin or paclitaxel

T. Naduvilath, D. Goldstein, M. Friedlander, 2021, Scientific Reports.

Nomogram for Estimating Overall Survival in Patients With Metastatic Pancreatic Cancer

M. Reni, J. Tabernero, D. V. Von Hoff, 2020, Pancreas.

Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy.

G. M. Briggs, N. Pavlakis, D. Goldstein, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Circulating pancreatic stellate (stromal) cells in pancreatic cancer-a fertile area for novel research.

S. Pothula, D. Goldstein, T. Becker, 2017, Carcinogenesis.

Effective delivery of siRNA into cancer cells and tumors using well-defined biodegradable cationic star polymers.

D. Goldstein, C. Boyer, S. Sagnella, 2013, Molecular pharmaceutics.

The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study.

D. Goldstein, R. Ward, N. Hawkins, 2016, The oncologist.

Pancreatic cancer: The microenvironment needs attention too!

S. Pothula, D. Goldstein, M. Apte, 2015, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT).

D. V. Von Hoff, G. Tortora, D. Goldstein, 2016, European journal of cancer.

A randomized trial comparing local recurrence (LR) rates between short-course (SC) and long-course (LC) preoperative radiotherapy (RT) for clinical T3 rectal cancer: An intergroup trial (TROG, AGITG, CSSANZ, RACS).

Trog, R. Fisher, D. Goldstein, 2010 .

Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity.

M. Friedlander, D. Goldstein, M. Kiernan, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.

M. Friedlander, D. Goldstein, M. Kiernan, 2009, Brain : a journal of neurology.

Oxaliplatin-Induced Lhermitte’s Phenomenon as a Manifestation of Severe Generalized Neurotoxicity

M. Friedlander, D. Goldstein, M. Kiernan, 2009, Oncology.

Modification of leucovorin dose within a simplified FOLFOX regimen improves tolerability without compromising efficacy.

P. Beale, M. Friedlander, S. Clarke, 2007, Clinical colorectal cancer.

Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity.

P. Beale, M. Friedlander, S. Clarke, 2006, Clinical colorectal cancer.

Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients

S. Clarke, P. Beale, M. Friedlander, 2005, British Journal of Cancer.

Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected].

V. Gebski, R. Simes, S. Clarke, 2011, European journal of cancer.

The impact on health-related quality of life in the first 12 months: A randomised comparison of preoperative short-course radiation versus long-course chemoradiation for T3 rectal cancer (Trans-Tasman Radiation Oncology Group Trial 01.04).

D. Goldstein, J. Zalcberg, R. Fisher, 2016, European journal of cancer.

Early results of quality of life for curatively treated rectal cancers in Chinese patients with EORTC QLQ-CR29

K. Goodman, D. Goldstein, S. Cai, 2011, Radiation oncology.

The AGITG GAP Study: A Phase II Study of Perioperative Gemcitabine and Nab-Paclitaxel for Resectable Pancreas Cancer

J. Kench, V. Gebski, I. Marschner, 2020, Annals of Surgical Oncology.

Early toxicity from preoperative radiotherapy with continuous infusion 5-fluorouracil for resectable adenocarcinoma of the rectum: a Phase II trial for the Trans-Tasman Radiation Oncology Group.

R. Fisher, D. Goldstein, D. Joseph, 2001, International journal of radiation oncology, biology, physics.

Patients’ Preferences for 3 Months vs 6 Months of Adjuvant Chemotherapy for Colon Cancer

M. Stockler, D. Goldstein, M. Jefford, 2020, JNCI cancer spectrum.

Is improving local control sufficient indication for radiotherapy in the management of rectal cancer? A response

D. Goldstein, J. Zalcberg, M. Solomon, 2003, ANZ journal of surgery.

Acute changes in nerve excitability following oxaliplatin treatment in mice.

D. Goldstein, Susanna B. Park, J. Howells, 2020, Journal of neurophysiology.

Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04.

D. Goldstein, J. Zalcberg, D. Joseph, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial.

L. Lipton, N. Pavlakis, Y. Bang, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Audit of postoperative chemoradiotherapy as adjuvant therapy for resected gastroesophageal adenocarcinoma: an Australian multicentre experience

P. Gibbs, D. Goldstein, C. Karapetis, 2004, ANZ journal of surgery.

Radiation Therapy Deviations in Trial of Locally Advanced Prostate Cancer-Reply.

D. Goldstein, P. Hammel, F. Huguet, 2016, JAMA.

Neuroendocrine tumours - models for rare tumour management

D. Goldstein, J. Zalcberg, D. L. Chan, 2015 .

Risk and response adapted therapy for early stage Hodgkin lymphoma: a prospective multicenter study of the Australasian Leukaemia and Lymphoma Group/Trans-Tasman Radiation Oncology Group

J. Reynolds, D. Goldstein, D. Joseph, 2011, Leukemia & lymphoma.

Antitumour effects and mechanisms of action of the panHER inhibitor, dacomitinib, alone and in combination with the STAT3 inhibitor, S3I-201, in human sarcoma cell lines.

D. Goldstein, Jia-Lin Yang, P. Crowe, 2018, International journal of oncology.

Blood Level of Phosphoglycerate Kinase Does not Correlate with Presence or Extent of Tumor

D. Beer, M. Friedlander, D. Goldstein, 2004, The International journal of biological markers.

Interferon-alpha promotes the anti-proliferative effect of Erlotinib (OSI-774) on human colon cancer cell lines.

D. Goldstein, P. Russell, Jia-Lin Yang, 2005, Cancer letters.

Potential applications of nanotechnology for the diagnosis and treatment of pancreatic cancer

D. Goldstein, C. Boyer, M. Kavallaris, 2013, Front. Physiol..

When is a GIST not a GIST? A case report of synchronous metastatic gastrointestinal stromal tumor and fibromatosis

D. Goldstein, Chee Khoon Lee, A. Hadley, 2009, World journal of surgical oncology.

Determining the CA19-9 concentration that best predicts the presence of CT-occult unresectable features in patients with pancreatic cancer: A population-based analysis.

W. McGahan, N. Merrett, D. Goldstein, 2020, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

Chemotherapy in patients with unresected pancreatic cancer in Australia: A population‐based study of uptake and survival

N. Merrett, D. Goldstein, V. Beesley, 2018, Asia-Pacific journal of clinical oncology.

I. Hickie, M. Friedlander, D. Goldstein, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II trial of filgrastim (r-metHuG-CSF), CEOP chemotherapy and antiretroviral therapy in HIV-related non-Hodgkin's lymphoma.

D. Cooper, D. Goldstein, J. Hoy, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Administration of imiquimod, an interferon inducer, in asymptomatic human immunodeficiency virus-infected persons to determine safety and biologic response modification.

D. Cooper, D. Goldstein, P. Hertzog, 1998, The Journal of infectious diseases.

Clinical features and predictors of survival of AIDS‐related non‐Hodgkin's lymphoma in a population‐based case series in Sydney, Australia

D. Goldstein, M. Law, Spiridon Cristina Monica, 2004, HIV medicine.

Cancer in older people: a tale of two disciplines

D. Goldstein, C. Steer, G. Marx, 2009, Internal medicine journal.

Multimodality treatment of oligometastatic anal squamous cell carcinoma: A case series and literature review

D. Goldstein, S. Thompson, F. Sclafani, 2019, Journal of surgical oncology.

Describing Patterns of Care in Pancreatic Cancer: A Population-Based Study

N. Merrett, D. Goldstein, V. Beesley, 2015, Pancreas.

Performance status dynamics during treatment with nab-paclitaxel plus gemcitabine versus gemcitabine alone for metastatic pancreatic cancer

D. V. Von Hoff, D. Goldstein, E. Chiorean, 2018, Cancer management and research.

Phase I / II trial of filgrastim ( r-metHuG-CSF ) , CEOP chemotherapy and antiretroviral therapy in HFV-related non-Hodgkin ' s lymphoma

D. Cooper, D. Goldstein, J. Hoy, 2005 .

Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey

L. Horvath, D. Goldstein, K. Webber, 2017, Supportive Care in Cancer.

Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates.

M. Hidalgo, M. Reni, J. Tabernero, 2013 .

Uncovering a key to the process of metastasis in human cancers: a review of critical regulators of anoikis

D. Goldstein, Jia-Lin Yang, P. Crowe, 2013, Journal of Cancer Research and Clinical Oncology.

Using a Delphi process to determine optimal care for patients with pancreatic cancer

N. Merrett, D. Goldstein, V. Beesley, 2015, Asia-Pacific journal of clinical oncology.

Circulating tumour cells in pancreatic cancer: A systematic review and meta-analysis of clinicopathological implications.

D. Goldstein, T. Becker, R. Pirola, 2020, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT).

M. Hidalgo, M. Reni, E. Van Cutsem, 2013 .

3008 ORAL Acute adverse events in a randomised trial of short course versus long course preoperative radiotherapy for T3 adenocarcinoma of rectum: a Trans-Tasman Radiation Oncology Group trial (TROG 01.04)

R. Fisher, D. Goldstein, D. Joseph, 2007 .

Refining the care of patients with pancreatic cancer: the AGITG Pancreatic Cancer Workshop consensus

J. Kench, J. Samra, A. Barbour, 2016, The Medical journal of Australia.

A Rationally Optimized Nanoparticle System for the Delivery of RNA Interference Therapeutics into Pancreatic Tumors in Vivo.

D. Goldstein, C. Boyer, S. Sagnella, 2016, Biomacromolecules.

A phase II study of liposomal doxorubicin in the treatment of HIV-related Kaposi's sarcoma.

D. Cooper, D. Goldstein, S. Milliken, 1998, Australian and New Zealand journal of medicine.

Regulation of epidermal growth factor receptor in human colon cancer cell lines by interferon α

D. Goldstein, P. Russell, Jia-Lin Yang, 2003 .

COLON Regulation of epidermal growth factor receptor in human colon cancer cell lines by interferon a

D. Goldstein, Xian-Jun Qu, P. Russell, 2003 .

Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer.

B. Vogelstein, P. Gibbs, L. Lipton, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Corneal nerve changes following treatment with neurotoxic anticancer drugs.

D. Goldstein, M. Markoulli, Susanna B. Park, 2021, The ocular surface.

Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial

R. Greil, U. Jaeger, W. Au, 2015, Haematologica.

Weekly Paclitaxel-Induced Neurotoxicity in Breast Cancer: Outcomes and Dose Response.

M. Friedlander, D. Goldstein, M. Kiernan, 2021, The oncologist.

A Cross-Sectional Study of Sub-Basal Corneal Nerve Reduction Following Neurotoxic Chemotherapy

D. Goldstein, M. Markoulli, K. Edwards, 2021, Translational vision science & technology.

Electrophysiological and phenotypic profiles of taxane-induced neuropathy

D. Goldstein, M. Kiernan, Susanna B. Park, 2020, Clinical Neurophysiology.

Chemotherapy-induced peripheral neuropathy—patient-reported outcomes compared with NCI-CTCAE grade

D. Goldstein, Susanna B. Park, J. McCrary, 2019, Supportive Care in Cancer.

Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP)

M. Moore, D. Goldstein, D. Vernerey, 2016, British Journal of Cancer.

EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma.

M. Stockler, N. Pavlakis, J. Thompson, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?

R. Figlin, R. Townsend, J. Rosenberg, 2016, European journal of cancer.

Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer.

M. Friedlander, D. Goldstein, M. Millward, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Primary pancreatic lymphoma – pancreatic tumours that are potentially curable without resection, a retrospective review of four cases

D. Goldstein, P. Grimison, M. Harrison, 2006, BMC Cancer.

Safety and pharmacokinetics (PK) of AMG 706 with panitumumab plus FOLFIRI or FOLFOX for the treatment of patients (pts) with metastatic colorectal cancer (mCRC)

H. Hurwitz, D. Goldstein, H. Burris, 2007 .

The association between quality care and outcomes for a real-world population of Australian patients diagnosed with pancreatic cancer.

J. Kench, N. Merrett, D. Goldstein, 2021, HPB : the official journal of the International Hepato Pancreato Biliary Association.

Ex vivo culture of intact human patient derived pancreatic tumour tissue

P. Timpson, D. Goldstein, L. Butler, 2021, Scientific reports.

Ex vivo culture of intact human patient derived pancreatic tumour tissue

D. Goldstein, L. Butler, E. Pandzic, 2020, Scientific Reports.

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer

M. Reni, J. Tabernero, D. V. Von Hoff, 2016, British Journal of Cancer.

Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study.

D. Goldstein, O. Bouché, F. Bonnetain, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Systemic treatment in advanced biliary cancers: A multicenter Australian analysis and review

D. Goldstein, K. Sjoquist, M. Aghmesheh, 2017, Asia-Pacific journal of clinical oncology.

Patients’ preferences for 3 months versus 6 months of adjuvant chemotherapy (ACT) for colon cancer in the SCOT trial: what survival benefits make longer chemotherapy worthwhile?

M. Stockler, D. Goldstein, M. Jefford, 2018 .

Meta‐analysis of radical resection rates and margin assessment in pancreatic cancer

J. Kench, V. Gebski, J. Samra, 2015, The British journal of surgery.

An international, randomized, open-label, phase III trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for surgically resected pancreatic adenocarcinoma (APACT): primary analysis and quality of life outcomes.

J. Berlin, P. Philip, M. Reni, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Human equilibrative nucleoside transporter 1 (hENT1) in gemcitabine and FOLFOX (oxaliplatin, 5-fluorouracil, and leucovorin)-treated patients with metastatic pancreatic cancer: The randomized phase II PAN1 study.

V. Gebski, J. Mackey, D. Goldstein, 2014 .

D. Goldstein, O. Bouché, F. Bonnetain, 2013, Journal of Clinical Oncology.

Chemotherapy and radiotherapy for pancreatic cancer

D. Goldstein, C. Steer, C. Karapetis, 2000 .

Chemotherapy made easier.

M. Friedlander, D. Goldstein, E. Segelov, 1993, Australian and New Zealand journal of medicine.

Rituximab to treat gemcitabine-induced hemolytic–uremic syndrome (HUS) in pancreatic adenocarcinoma: a case series and literature review

D. Goldstein, M. Fernando, Georgia Ritchie, 2016, Cancer Chemotherapy and Pharmacology.

LBA-06INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib (REG) in refractory advanced oesophagogastric cancer (AOGC) - A study by the Australasian Gastrointestinal Trials Group (AGITG): Final overall and subgroup results

L. Lipton, N. Pavlakis, Y. Bang, 2015 .

INTEGRATE: A randomized, phase II, double-blind, placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC): A study by the Australasian Gastrointestinal Trials Group (AGITG)—Final overall and subgroup results.

L. Lipton, N. Pavlakis, Y. Bang, 2015 .

The potential of circulating tumor DNA (ctDNA) to guide adjuvant chemotherapy decision making in locally advanced rectal cancer (LARC).

K. Kinzler, B. Vogelstein, P. Gibbs, 2017 .

Nomogram for predicting overall survival (OS) in patients (pts) treated with nab-paclitaxel (nab-P) plus gemcitabine (Gem) or Gem alone for metastatic pancreatic cancer (MPC).

M. Reni, J. Tabernero, D. Goldstein, 2017 .

Chemotherapy and peripheral neuropathy

D. Goldstein, M. Kiernan, Susanna B. Park, 2021, Neurological Sciences.

The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours

J. Desai, N. Pavlakis, A. Nagrial, 2022, Targeted Oncology.

Targeting the HGF/c-MET pathway: stromal remodelling in pancreatic cancer

S. Pothula, N. Merrett, D. Goldstein, 2017, Oncotarget.

Multimodal quantitative examination of nerve function in colorectal cancer patients prior to chemotherapy

D. Goldstein, M. Kiernan, M. Farrar, 2018, Muscle & nerve.

What is the gender representation in authorship in later phase systemic clinical trials in biliary tract cancer (BTC)? - a retrospective review of the published literature

J. Furuse, R. Kelley, M. Lowery, 2022, BMJ Open.

Inflammatory Markers Have a Role in Renal Cell Carcinoma Prognosis.

S. Clarke, D. Goldstein, W. Chua, 2016, European urology focus.

ESPAC-3(v2): A multicenter, international, open-label, randomized controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma.

D. Smith, J. Neoptolemos, D. Stocken, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Value of central review of RECIST v1.1 outcomes in the AGITG INTEGRATE randomised phase 2 international trial for advanced oesophago-gastric cancer

M. Stockler, V. Gebski, D. Moses, 2022, Journal of Cancer Research and Clinical Oncology.

Neu-horizons: neuroprotection and therapeutic use of riluzole for the prevention of oxaliplatin-induced neuropathy—a randomised controlled trial

M. Friedlander, D. Goldstein, M. Kiernan, 2020, Supportive Care in Cancer.

APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.

J. Berlin, A. Biankin, P. Philip, 2019, Journal of Clinical Oncology.

Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial

David Goldstein, John Bridgewater, Alexander Stein, 2015 .

Dorsal root ganglion explants derived from chemotherapy-treated mice have reduced neurite outgrowth in culture

D. Goldstein, Gila Moalem-Taylor, J. Lees, 2019, Neuroscience Letters.

Impact of chemoradiotherapy (CRT) on local control and time without treatment in patients with locally advanced pancreatic cancer (LAPC) included in the international phase III LAP 07 study.

D. Goldstein, N. Spry, D. Vernerey, 2014 .

A randomized study of paclitaxel versus cyclophosphamide/methotrexate/5-fluorouracil/prednisone in previously untreated patients with advanced breast cancer: preliminary results. Taxol Investigational Trials Group, Australia/New Zealand.

D. Goldstein, M. Tattersall, S. Ackland, 1997, Seminars in Oncology.

Paclitaxel as first-line treatment for metastatic breast cancer. The Taxol Investigational Trials Group, Australia and New Zealand.

D. Goldstein, M. Tattersall, S. Ackland, 1997, Oncology.

Castleman's disease and HIV infection in Australia

D. Goldstein, K. Clezy, M. Chipman, 2004, HIV medicine.

Targeting the PI3K/PTEN/AKT/mTOR Pathway in Treatment of Sarcoma Cell Lines.

D. Goldstein, Jia-Lin Yang, P. Crowe, 2016, Anticancer research.

Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial

Joon-Oh Park, J. Berlin, A. Biankin, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reply to A. Giacalone et al

D. Goldstein, K. Webber, A. Lloyd, 2012 .

Clinical assessment of chemotherapy-induced peripheral neuropathy: a discrete choice experiment of patient preferences

D. Street, R. Viney, D. Goldstein, 2021, Supportive Care in Cancer.

Cicatricial pemphigoid in non‐Hodgkin's lymphoma

D. Goldstein, A. MacKenzie‐Wood, J. Shannon, 2003, Internal medicine journal.

Destructive soft tissue metastases in advanced colorectal cancer: a case report.

D. Goldstein, M. Krasovitsky, 2021, Annals of palliative medicine.

Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. The International SL-DOX Study Group.

H. Jablonowski, D. Goldstein, M. Goos, 1996, British Journal of Cancer.

Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence

D. Goldstein, Jia-Lin Yang, P. Crowe, 2016, OncoTargets and therapy.

Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review

D. Goldstein, M. Kiernan, Susanna B. Park, 2021, Journal of Cancer Survivorship.

The median informs the message: accuracy of individualized scenarios for survival time based on oncologists' estimates.

B. Kiely, M. Tattersall, M. Stockler, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeting the undruggable in pancreatic cancer using nano-based gene silencing drugs.

D. Goldstein, C. Boyer, R. M. Ignacio, 2020, Biomaterials.

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kazuhiro Yoshida, A. Benson, Y. Bang, 2018, The Lancet.

Elevated α-foetoprotein and hepatic metastases—it’s not always what it seems!

D. Goldstein, A. Boyce, G. Marx, 2002 .

A double blind, placebo controlled, phase II randomised cross-over trial investigating the use of duloxetine for the treatment of chemotherapy-induced peripheral neuropathy.

D. Goldstein, E. Barnes, Susanna B. Park, 2018, Contemporary clinical trials.

Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies.

M. Friedlander, D. Goldstein, M. Kiernan, 2008, Current medicinal chemistry.

The synergistic inhibitory effect of combining therapies targeting EGFR and mitochondria in sarcomas

D. Goldstein, Jia-Lin Yang, P. Hogg, 2020, Oncotarget.

Multicentric Castleman's disease treated with antivirals and immunosuppressants

D. Goldstein, A. Lloyd, S. Senanayake, 2003, Journal of medical virology.

Targeted therapy in soft tissue sarcoma-a novel direction in therapeutics.

D. Goldstein, Jia-Lin Yang, P. Crowe, 2013, Chinese clinical oncology.

Targeted therapy in soft tissue sarcoma-a novel direction in therapeutics.

D. Goldstein, Jia-Lin Yang, P. Crowe, 2013, Chinese clinical oncology.

Overcoming resistance of targeted EGFR monotherapy by inhibition of STAT3 escape pathway in soft tissue sarcoma

N. Zeps, D. Goldstein, Jia-Lin Yang, 2016, Oncotarget.

Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer

A. Biankin, S. Pothula, D. Goldstein, 2016, British Journal of Cancer.

Exploiting Base Excision Repair to Improve Therapeutic Approaches for Pancreatic Cancer

D. Goldstein, P. Phillips, J. McCarroll, 2015, Front. Nutr..

Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.

H. Friess, M. Büchler, J. Neoptolemos, 2010, JAMA.

Predictors of care for patients with cancer of unknown primary site in three Australian hospitals

D. Goldstein, R. Ward, C. Vajdic, 2018, Asia-Pacific journal of clinical oncology.

nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.

W. Scheithauer, J. Tabernero, V. Heinemann, 2015, Journal of the National Cancer Institute.

Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition

V. Gebski, M. Pajic, P. Timpson, 2020, Cancer Research.

Oxaliplatin induces muscle loss and muscle‐specific molecular changes in Mice

J. Kwok, D. Goldstein, P. Polly, 2018, Muscle & nerve.

Pancreatic stellate cells and pancreatic cancer cells: an unholy alliance.

D. Goldstein, R. Pirola, M. Apte, 2008, Cancer research.

Cancer Cells Pancreatic Stellate Cells : Partners in Crime with Pancreatic

D. Goldstein, R. Pirola, M. Apte, 2008 .

Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer

D. Goldstein, N. Spry, M. Michael, 2007, British Journal of Cancer.

Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial.

I. Hickie, M. Stockler, R. Simes, 2007, The Lancet. Oncology.

Interferon-α Promotes the Anti-Proliferative Effect of Gefitinib (ZD1839) on Human Colon Cancer Cell Lines

D. Goldstein, P. Russell, Jia-Lin Yang, 2005, Oncology.

βIII-Tubulin: A novel mediator of chemoresistance and metastases in pancreatic cancer

David Goldstein, Maria Kavallaris, Andrew V. Biankin, 2014, Oncotarget.

Cancer of unknown primary site.

D. Goldstein, C. Vajdic, 2015, Australian family physician.

Does the Microenvironment Hold the Hidden Key for Functional Precision Medicine in Pancreatic Cancer?

D. Goldstein, P. Phillips, J. McCarroll, 2021, Cancers.

The role of the hepatocyte growth factor/c-MET pathway in pancreatic stellate cell-endothelial cell interactions: antiangiogenic implications in pancreatic cancer.

S. Pothula, D. Goldstein, R. Pirola, 2014, Carcinogenesis.

Tumorigenesis and Neoplastic Progression Role of Pancreatic Stellate Cells in Pancreatic Cancer Metastasis

A. Biankin, D. Goldstein, R. Pirola, 2010 .

The impact of gemcitabine chemotherapy and 3D conformal RT/5FU on quality of life of patients managed for pancreatic cancer

D. Goldstein, G. Halkett, N. Spry, 2013 .

Impact of gemcitabine chemotherapy and 3-dimensional conformal radiation therapy/5-fluorouracil on quality of life of patients managed for pancreatic cancer.

D. Goldstein, A. Kneebone, G. Halkett, 2013, International journal of radiation oncology, biology, physics.

The GOFURTGO Study: AGITG Phase II Study of fixed dose rate gemcitabine–oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer

V. Gebski, D. Goldstein, S. Ackland, 2011, British Journal of Cancer.

Advances in Treatment Options for Patients with Pancreatic Cancer

D. Goldstein, C. Harris, 2009 .

3D radiotherapy can be safely combined with sandwich systemic gemcitabine chemotherapy in the management of pancreatic cancer: factors influencing outcome.

D. Goldstein, B. Iacopetta, A. Kneebone, 2008, International journal of radiation oncology, biology, physics.

Management of metastatic renal cell carcinoma in the era of targeted therapies

D. Goldstein, K. Webber, D. Yip, 2011, Internal medicine journal.

Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty

N. Pavlakis, F. Lordick, A. Nagrial, 2021, Expert review of anticancer therapy.

Prognosis of Kaposi's sarcoma as an initial and later AIDS associated illness.

J. Kaldor, D. Goldstein, M. Law, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Monitoring quality of care for patients with pancreatic cancer: a modified Delphi consensus.

J. Kench, L. Lipton, L. Chantrill, 2019, HPB : the official journal of the International Hepato Pancreato Biliary Association.

Compression of liver parenchyma by a malignant hepatic cyst

S. Riordan, D. Goldstein, G. Keogh, 2003 .

Compression of liver parenchyma by a malignant hepatic cyst: a previously unreported manifestation of metastatic gastric cancer

S. Riordan, D. Goldstein, G. Keogh, 2003, American Journal of Gastroenterology.

Quantification of Small Fiber Neuropathy in Chemotherapy Treated Patients.

L. Horvath, D. Goldstein, M. Kiernan, 2019, The journal of pain : official journal of the American Pain Society.

Characteristics and risk factors of bortezomib induced peripheral neuropathy: A systematic review of phase III trials

D. Goldstein, M. Kiernan, Susanna B. Park, 2019, Hematological oncology.

Neurophysiological and clinical outcomes in chemotherapy-induced neuropathy in cancer

L. Horvath, D. Goldstein, P. Grimison, 2017, Clinical Neurophysiology.

Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib.

J. Blay, E. Wardelmann, S. Litière, 2020, JAMA surgery.

Determinants of Outcomes Following Resection for Pancreatic Cancer—a Population-Based Study

N. Merrett, D. Goldstein, V. Beesley, 2016, Journal of Gastrointestinal Surgery.

STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers (review).

D. Goldstein, Jia-Lin Yang, P. Crowe, 2012, International journal of oncology.

Key role of pancreatic stellate cells in pancreatic cancer.

S. Pothula, D. Goldstein, R. Pirola, 2016, Cancer letters.

The Potential of panHER Inhibition in Cancer

D. Goldstein, Jia-Lin Yang, P. Crowe, 2015, Front. Oncol..

Chemotherapy‐induced peripheral neurotoxicity: A critical analysis

M. Koltzenburg, M. Friedlander, D. Goldstein, 2013, CA: a cancer journal for clinicians.

Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial

J. Blay, G. Demetri, Yoon-Koo Kang, 2016, BMC Cancer.

Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure

David Goldstein, Serge Leyvraz, Patrick Schöffski, 2012, Clinical Cancer Research.

Consensus approaches to best practice management of gastrointestinal stromal tumors

S. Fox, J. Desai, D. Goldstein, 2008 .

Response of Carney's triad‐related metastatic gastrointestinal stromal tumor to sunitinib

D. Goldstein, D. Yip, G. Pranavan, 2008 .

HGF/c-Met Inhibition as Adjuvant Therapy Improves Outcomes in an Orthotopic Mouse Model of Pancreatic Cancer

Susan M. Corley, M. Wilkins, S. Pothula, 2021, Cancers.

Phase II study of paclitaxel and oral etoposide in patients with locally advanced or metastatic non-small cell lung cancer.

S. Clarke, D. Goldstein, M. Millward, 2001, Lung cancer.

Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer

S. Clarke, D. Goldstein, B. Iacopetta, 2009, British Journal of Cancer.

AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer

V. Gebski, Mark T Lee, L. Chantrill, 2021, BMC cancer.

The impact of anticancer drugs on the ocular surface.

D. Goldstein, M. Markoulli, A. Semmler, 2020, The ocular surface.

EUS-FNA Biopsies to Guide Precision Medicine in Pancreatic Cancer: Results of a Pilot Study to Identify KRAS Wild-Type Tumours for Targeted Therapy

V. Gebski, D. Goldstein, J. Zalcberg, 2021, Frontiers in Oncology.

Predictive value of neutrophils count for local tumor control after chemoradiotherapy in patients with locally advanced pancreatic carcinoma.

P. van Houtte, D. Goldstein, A. Schernberg, 2021, International journal of radiation oncology, biology, physics.

Evaluation of Phase II Trial Design in Advanced Pancreatic Cancer.

I. Marschner, R. Simes, D. Goldstein, 2019, Pancreas.

CanStem111P trial: a Phase III study of napabucasin plus nab-paclitaxel with gemcitabine.

M. Reni, E. Van Cutsem, J. Tabernero, 2019, Future oncology.

Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease.

R. Labianca, H. Friess, J. Berlin, 2018, The Lancet. Oncology.

Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty

F. Lordick, L. Chantrill, D. Goldstein, 2017, Expert review of anticancer therapy.

Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With nab-Paclitaxel and Gemcitabine

D. V. Von Hoff, D. Goldstein, S. Ferrara, 2016, Pancreas.

Delineating the Role of βIV-Tubulins in Pancreatic Cancer: βIVb-Tubulin Inhibition Sensitizes Pancreatic Cancer Cells to Vinca Alkaloids12

A. Biankin, A. Johns, D. Goldstein, 2016, Neoplasia.

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer

M. Reni, J. Tabernero, D. V. Von Hoff, 2016, British Journal of Cancer.

Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial.

W. Scheithauer, D. V. Von Hoff, D. Goldstein, 2016, Journal of gastrointestinal oncology.

Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.

W. Scheithauer, J. Tabernero, D. V. Von Hoff, 2015, The oncologist.

Gastrointestinal Cancer PrognosticFactorsofSurvival inaRandomizedPhaseIIITrial ( MPACT ) of Weekly nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer

Darryl, Infante, Ñ., 2015 .

Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer.

M. Tattersall, D. Goldstein, M. Tattersall, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Initial P aclitaxel I mproves O utcome C ompared W ith C MFP Combination C hemotherapy a s F ront-Line T herapy in U ntreated M etastatic B reast C ancer

D. Goldstein, S. Ackland, J. Dewar, 1999 .

Gastrointestinal Stromal Tumours: Correlation of 18F-FDG Gamma Camera-Based Coincidence Positron Emission Tomography with CT for the Assessment of Treatment Response – An AGITG Study

D. Goldstein, M. Rossleigh, W. Haindl, 2005, Oncology.

Impact of STAT3 inhibition on survival of osteosarcoma cell lines.

D. Goldstein, Jia-Lin Yang, P. Crowe, 2014, Anticancer research.

Mobility in survivors with chemotherapy-induced peripheral neuropathy and utility of the 6-min walk test

D. Goldstein, R. Henderson, Susanna B. Park, 2019, Journal of Cancer Survivorship.

Tamoxifen use in retroperitoneal fibrosis

D. Goldstein, C. Harris, 2010, Internal medicine journal.

Biliary Stenting in Patients With Pancreatic Cancer: Results From a Population-Based Cohort Study

N. Merrett, D. Goldstein, V. Beesley, 2017, Pancreas.

Association between pancreatic cancer patients' perception of their care coordination and patient-reported and survival outcomes

Jane M. Young, N. Merrett, D. Goldstein, 2017, Palliative and Supportive Care.

Anxiety, depression and quality of life in people with pancreatic cancer and their carers.

K. Klein, N. Merrett, D. Goldstein, 2017, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

Factors associated with quality of care for patients with pancreatic cancer in Australia

N. Merrett, D. Goldstein, V. Beesley, 2016, The Medical journal of Australia.

Determinants of survival and attempted resection in patients with non-metastatic pancreatic cancer: An Australian population-based study.

N. Merrett, D. Goldstein, V. Beesley, 2016, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

Risk factors for current and future unmet supportive care needs of people with pancreatic cancer. A longitudinal study

N. Merrett, D. Goldstein, V. Beesley, 2016, Supportive Care in Cancer.

Immunohistochemistry for SDHB Divides Gastrointestinal Stromal Tumors (GISTs) into 2 Distinct Types

A. Chou, J. Samra, A. Gill, 2010, The American journal of surgical pathology.

Good survival outcome of metastatic SDH-deficient gastrointestinal stromal tumors harboring SDHA mutations

G. Rossi, M. Fiorentino, D. Goldstein, 2014, Genetics in Medicine.

Pancreatic stellate cells: partners in crime with pancreatic cancer cells.

David Goldstein, Swapna Joshi, D. Goldstein, 2008, Cancer research.

Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients

Mellar P. Davis, R. Motzer, M. Michaelson, 2015, British Journal of Cancer.

Impact of oxaliplatin-induced neuropathy: a patient perspective

M. Friedlander, D. Goldstein, M. Kiernan, 2012, Supportive Care in Cancer.

The successful management of two pregnancies with wild type metastatic gastrointestinal stromal tumors

D. Goldstein, D. Yip, C. Hemmings, 2009 .

Management of metastatic gastrointestinal stromal tumour in the Glivec era: a practical case‐based approach

D. Goldstein, M. L. Harrison, 2006, Internal medicine journal.

Determinants of outcomes following resection for pancreatic cancer – An Australian population-based study

N. Merrett, D. Goldstein, V. Beesley, 2015 .

Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study.

M. Büchler, J. Neoptolemos, J. Izbicki, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Initial survival outcomes for the AGITG GAP study – a phase II study of perioperative nab-paclitaxel and gemcitabine for resectable pancreatic ductal adenocarcinoma (PDAC).

J. Kench, V. Gebski, N. Pavlakis, 2016 .

APACT: Phase III randomized trial of adjuvant treatment with nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone in patients (pts) with resected pancreatic cancer (PC).

A. Biankin, P. Philip, M. Tempero, 2016 .

Barriers and enablers to the implementation of multidisciplinary team meetings: a qualitative study using the theoretical domains framework

J. Kench, N. Merrett, Sally E. Green, 2020, BMJ Quality & Safety.

Prognostic factors predictive of response and survival to a modified FOLFOX regimen: importance of an increased neutrophil count.

M. Friedlander, S. Clarke, D. Goldstein, 2006, Clinical colorectal cancer.

Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer

M. Büchler, J. Mackey, W. Greenhalf, 2018, British Journal of Cancer.

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer

M. Reni, J. Tabernero, D. V. Von Hoff, 2016, British Journal of Cancer.

CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer

M. Reni, J. Tabernero, D. V. Von Hoff, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas

R. Korn, J. Tabernero, D. V. Von Hoff, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Hypersensitivity reactions to oxaliplatin: Can patients be rechallenged?

D. Goldstein, Kelly W Mok, 2006 .

Targeting HGF/c-MET Axis in Pancreatic Cancer

S. Pothula, D. Goldstein, R. Pirola, 2020, International journal of molecular sciences.

The Upper Gastrointestinal Cancer Registry (UGICR): a clinical quality registry to monitor and improve care in upper gastrointestinal cancers

J. Kench, L. Lipton, J. McNeil, 2019, BMJ Open.

The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma

J. Kleeff, M. Büchler, J. Neoptolemos, 2017, Annals of surgery.

A multicenter, phase II trial of preoperative gemcitabine and nab-paclitaxel for resectable pancreas cancer: The AGITG GAP study.

J. Kench, V. Gebski, N. Pavlakis, 2015 .

Australian Leukaemia Study Group Myeloma II: a randomized trial of intensive combination chemotherapy with or without interferon in patients with myeloma

D. Goldstein, J. Matthews, R. Penny, 1997, British journal of haematology.

Reply letter to comments on: Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis

S. Pothula, D. Goldstein, R. Pirola, 2020, British Journal of Cancer.

Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis

S. Pothula, D. Goldstein, R. Pirola, 2020, British Journal of Cancer.

Characterisation of Immune and Neuroinflammatory Changes Associated with Chemotherapy-Induced Peripheral Neuropathy

D. Goldstein, O. Butovsky, Susanna B. Park, 2017, PloS one.

Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3.

M. Brundage, D. Tu, W. Parulekar, 2016, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer.

D. Goldstein, C. Steer, C. Karapetis, 2009, The Cochrane database of systematic reviews.

Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study.

M. van Glabbeke, R. Sciot, J. Verweij, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Modern management of pancreatic carcinoma

D. Goldstein, G. Keogh, S. Carroll, 2004, Internal medicine journal.

An unusual case of malignant melanoma of the small intestine.

A. Gelb, D. Goldstein, D. H. Goldstein, 1984, The American journal of gastroenterology.

Clinical and molecular profile of young adults with early‐onset colorectal cancer: Experience from four Australian tertiary centers

N. Pavlakis, L. Chantrill, D. Goldstein, 2022, Asia-Pacific journal of clinical oncology.

A PILOT STUDY OF PREOPERATIVE AND POSTOPERATIVE CHEMOTHERAPY IN PATIENTS WITH OPERABLE GASTRIC CANCER: AUSTRALASIAN GASTROINTESTINAL TRIALS GROUP STUDY 9601

V. Gebski, D. Goldstein, H. Dhillon, 2007, ANZ journal of surgery.

Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer

J. Mackey, W. Greenhalf, J. Neoptolemos, 2018, British Journal of Cancer.

Clinical and molecular characterization of HER2 amplified-pancreatic cancer

J. Pearson, A. Biankin, M. Pajic, 2013, Genome Medicine.

Addition of gabapentin (G) to a modified FOLFOX regimen does not reduce neurotoxicity in patients (pts) with advanced colorectal cancer (CRC)

S. Clarke, P. Beale, M. Friedlander, 2005 .

Exercise-based rehabilitation for cancer survivors with chemotherapy-induced peripheral neuropathy

L. Horvath, B. Barry, D. Goldstein, 2019, Supportive Care in Cancer.

Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy

M. Büchler, J. Mackey, W. Greenhalf, 2018, British Journal of Cancer.

Oxaliplatin‐induced neurotoxicity and the development of neuropathy

M. Friedlander, D. Goldstein, M. Kiernan, 2005, Muscle & nerve.

A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): case series of 28 patients.

A. Godwin, H. Joensuu, A. Lazar, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Chemotherapy influencing the course of nephrotic syndrome in colonic carcinoma

R. Penny, D. Goldstein, J. Hayes, 1987, Medical oncology and tumor pharmacotherapy.

The role of chemotherapy in gastric cancer-related microangiopathic haemolytic anaemia.

D. Goldstein, Monica Tang, 2017, Journal of gastrointestinal oncology.

Patient-reported outcome measures (PROMs) in pancreatic cancer: a systematic review.

N. Merrett, D. Goldstein, J. Zalcberg, 2020, HPB : the official journal of the International Hepato Pancreato Biliary Association.

Changes in epidermal growth factor receptor expression in human bladder cancer cell lines following interferon-alpha treatment.

D. Goldstein, P. Russell, Jia-Lin Yang, 2004, The Journal of urology.

Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review

D. Goldstein, M. Kiernan, Susanna B. Park, 2021, Journal of Cancer Survivorship.

Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy

D. Goldstein, P. Grimison, R. Henderson, 2021, JAMA network open.

The impact of obesity on neuropathy outcomes for paclitaxel- and oxaliplatin-treated cancer survivors

M. Friedlander, L. Horvath, D. Goldstein, 2021, Journal of Cancer Survivorship.

Neuroprotection for oxaliplatin-induced neurotoxicity: what happened to objective assessment?

M. Friedlander, D. Goldstein, M. Kiernan, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer

H. Hurwitz, D. Goldstein, H. Burris, 2015, Cancer Chemotherapy and Pharmacology.

Balance Deficits and Functional Disability in Cancer Survivors Exposed to Neurotoxic Cancer Treatments.

M. Friedlander, D. Goldstein, J. Menant, 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

Rituximab Maintenance Significantly Prolongs Event Free (EFS) and Progression Free Survival (PFS) In Male Patients With Aggressive B-Cell Lymphoma In The NHL13 Study

R. Greil, U. Jaeger, W. Au, 2013 .

Significance of Phosphorylated Epidermal Growth Factor Receptor and Its Signal Transducers in Human Soft Tissue Sarcoma

D. Goldstein, Jia-Lin Yang, P. Crowe, 2017, International journal of molecular sciences.

Resistance to imatinib, low-grade FDG-avidity on PET, and acquired KIT exon 17 mutation in gastrointestinal stromal tumour.

D. Goldstein, G. McArthur, P. Waring, 2005, The Lancet. Oncology.

Immune-mediated processes implicated in chemotherapy-induced peripheral neuropathy.

D. Goldstein, Susanna B. Park, J. Lees, 2017, European journal of cancer.

Progress in the Treatment of Small Intestine Cancer

D. Goldstein, M. Aghmesheh, R. Gandy, 2023, Current Treatment Options in Oncology.

Effect of exercise on neuromuscular toxicity in oxaliplatin‐treated mice

D. Goldstein, Susanna B. Park, J. Lees, 2021, Muscle & nerve.

If I am in the mood, I enjoy it: an exploration of cancer-related fatigue and sexual functioning in women with breast cancer.

M. Friedlander, D. Goldstein, K. Webber, 2011, The oncologist.

Randomized multicenter phase III study in patients with locally advanced adenocarcinoma of the pancreas: Gemcitabine with or without chemoradiotherapy and with or without erlotinib-LAP 07 study.

D. Goldstein, F. Bonnetain, B. Glimelius, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Landmark survival analysis and impact of anatomic origin in prospective clinical trials of biliary tract cancer.

T. Bekaii-Saab, D. Goldstein, D. Cunningham, 2020, Journal of hepatology.

MutY-Homolog (MYH) inhibition reduces pancreatic cancer cell growth and increases chemosensitivity

A. Biankin, A. Johns, A. Mawson, 2016, Oncotarget.

D. Goldstein, J. Bridgewater, A. Lohse, 2015, BMC Cancer.

The effect of anti-angiogenic agents on overall survival in metastatic oesophago-gastric cancer: A systematic review and meta-analysis

N. Pavlakis, Y. Bang, Yoon-Koo Kang, 2017, PloS one.

Cerebral relapse of metastatic gastrointestinal stromal tumor during treatment with imatinib mesylate: Case report

D. Goldstein, P. Waring, D. Yip, 2004, BMC Cancer.

Adjuvant chemotherapy for early colon cancer: what survival benefits make it worthwhile?

M. Stockler, P. Beale, S. Clarke, 2010, European journal of cancer.

Inequity in rural cancer survival in Australia is not an insurmountable problem

D. Goldstein, P. Grogan, C.R. Underhill, 2006, The Medical journal of Australia.

N. Pavlakis, D. Goldstein, J. Simes, 2018, Gastric Cancer.

Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials

T. Bekaii-Saab, D. Goldstein, D. Cunningham, 2017, BMC Cancer.

This Work Is Licensed under a Creative Commons Attribution-noncommercial 4.0 License Repository Citation

M. Reni, J. Tabernero, D. Goldstein, 2022 .

Phase II trial PD-L1/PD-1 blockade avelumab with chemoradiotherapy for locally advanced resectable T3B-4/N1-2 rectal cancer: The Ave-Rec trial.

N. Pavlakis, J. Tie, D. Goldstein, 2019, Journal of Clinical Oncology.

Optimising clinical screening for chemotherapy-induced peripheral neuropathy.

M. Friedlander, D. Goldstein, Susanna B. Park, 2019, Journal of pain and symptom management.

CA 19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial ( MPACT ) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients withmetastatic pancreatic cancer

M. Reni, J. Tabernero, D. Goldstein, 2016 .

Dose Effects of Oxaliplatin on Persistent and Transient Na+ Conductances and the Development of Neurotoxicity

M. Friedlander, D. Goldstein, M. Kiernan, 2011, PloS one.

Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib.

J. Verweij, H. Joensuu, R. Maki, 2015, European journal of cancer.

Randomized Evaluation of Cognitive-Behavioral Therapy and Graded Exercise Therapy for Post-Cancer Fatigue.

M. Friedlander, B. Barry, D. Goldstein, 2017, Journal of pain and symptom management.

A Randomized Phase II Trial of Pemetrexed plus Irinotecan (ALIRI) versus Leucovorin-Modulated 5-FU plus Irinotecan (FOLFIRI) in First-Line Treatment of Locally Advanced or Metastatic Colorectal Cancer

D. Goldstein, C. Kaiser, V. Gorbounova, 2008, Oncology.

Barriers and enablers to the implementation of protocol-based imaging in pancreatic cancer: A qualitative study using the theoretical domains framework

Peter Evans, Ashika D Maharaj, Sue M Evans, 2020, PloS one.

Erlotinib (OSI‐774)‐induced inhibition of transitional cell carcinoma of bladder cell line growth is enhanced by interferon‐α

V. Hayes, P. Brenner, D. Goldstein, 2007, BJU international.

Phase II trial of nab-paclitaxel as first-line therapy of hormone refractory metastatic prostate cancer (HRPC).

T. Kolevska, D. Goldstein, B. Fireman, 2009, Journal of Clinical Oncology.

Accuracy and Prognostic Significance of Oncologists' Estimates and Scenarios for Survival Time in Advanced Gastric Cancer.

B. Kiely, M. Stockler, N. Pavlakis, 2019, The oncologist.

Investigation of Relation of Radiation Therapy Quality With Toxicity and Survival in LAP07 Phase 3 Trial for Locally Advanced Pancreatic Carcinoma.

P. van Houtte, D. Goldstein, N. Spry, 2021, International journal of radiation oncology, biology, physics.

Self-reported health, lifestyle and social circumstances of Australian adult cancer survivors: A propensity score weighted cross-sectional study.

D. Goldstein, K. Webber, M. Harris, 2020, Cancer epidemiology.

Current Care And Needs Of Adult Cancer Survivors-A Cross-sectional Survey Asia Pacific

M. Friedlander, D. Goldstein, K. Webber, 2012 .

Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab.

R. Simes, L. Chantrill, D. Goldstein, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

A tsunami of unmet needs: pancreatic and ampullary cancer patients' supportive care needs and use of community and allied health services

N. Merrett, D. Goldstein, V. Beesley, 2016, Psycho-oncology.

INTEGRATE IIa: A randomised, double-blind, phase III study of regorafenib versus placebo in refractory advanced gastro-oesophageal cancer (AGOC)—A study led by the Australasian Gastro-intestinal Trials Group (AGITG).

N. Pavlakis, Y. Bang, D. Goldstein, 2023, Journal of Clinical Oncology.

The experience of cancer-related fatigue and chronic fatigue syndrome: a qualitative and comparative study.

I. Hickie, M. Friedlander, D. Goldstein, 2007, Journal of pain and symptom management.

End-stage liver disease and liver transplant: current situation and key issues.

Y. Ni, D. Goldstein, A. Dhawan, 2008, Journal of pediatric gastroenterology and nutrition.

1133 PANCREATIC STELLATE CELL AND CANCER CELL DERIVED EXOSOMES IMPAIR BETA CELL FUNCTION: IMPLICATIONS FOR PANCREATIC CANCER RELATED DIABETES.

S. Pothula, S. Chari, D. Goldstein, 2020 .

Outpatient treatment with subcutaneous interleukin‐2, interferon alpha and fluorouracil in patients with metastatic renal cancer: an Australian experience

D. Goldstein, J. Taylor, G. Marx, 2005, Internal medicine journal.

INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC)--A study by the Australasian Gastrointestinal Trials Group (AGITG), first results.

L. Lipton, N. Pavlakis, Y. Bang, 2015 .

Promising Results of a Cooperative Group Phase II Trial of Preoperative Chemoradiation for Locally Advanced Rectal Cancer (TROG 9801)

D. Goldstein, D. Joseph, R. Fisher, 2005, Diseases of the colon and rectum.

Correlation of phase 2 trials (Ph2t) results with outcomes of phase 3 trials (Ph3t) of investigational agents (IA) in locally advanced and metastatic pancreas cancer (LAMPC).

I. Marschner, D. Goldstein, J. Simes, 2017 .

Prognostic factors for progression-free and overall survival in advanced biliary tract cancer.

D. Goldstein, D. Cunningham, J. Bridgewater, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

A cross-sectional study of ocular surface discomfort and corneal nerve dysfunction after paclitaxel treatment for cancer

D. Goldstein, M. Markoulli, Susanna B. Park, 2021, Scientific reports.

Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors

N. Pavlakis, D. Goldstein, N. Waterhouse, 2023, Journal for ImmunoTherapy of Cancer.

WITHDRAWN: Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer.

D. Goldstein, C. Steer, C. Karapetis, 2009, The Cochrane database of systematic reviews.

Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas

V. Gebski, D. Goldstein, M. Jefford, 2011, Cancer Chemotherapy and Pharmacology.

Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial

M. Reni, E. Van Cutsem, J. Tabernero, 2023, EClinicalMedicine.

Predictors of resilience in women treated for breast cancer: A prospective study

M. Friedlander, D. Goldstein, K. Webber, 2012 .

Cancer survivorship outcomes in immigrants.

P. Butow, M. King, D. Goldstein, 2012 .

Managing HIV. Part 5: Treating secondary outcomes. 5.14 HIV and Kaposi's sarcoma.

K. Gelmon, D. Goldstein, J. Millar, 1996, Medical Journal of Australia.

The impact of neutrophil-lymphocyte ratio on risk reclassification of patients with advanced renal cell cancer to guide risk-directed therapy

V. Gebski, R. Motzer, S. Clarke, 2020, Acta oncologica.

Challenges and solutions to sharing a cancer follow-up e-care plan between a cancer service and general practice.

J. Taggart, D. Goldstein, M. Harris, 2021, Public health research & practice.

Characterization of Fatigue States in Medicine and Psychiatry by Structured Interview

I. Hickie, U. Vollmer-Conna, D. Goldstein, 2014, Psychosomatic medicine.

Circulating tumor DNA as a prognostic biomarker in early stage pancreatic cancer.

K. Kinzler, B. Vogelstein, P. Gibbs, 2018 .

Diffuse alveolar damage following a single administration of a cyclophosphamide containing chemotherapy regimen.

D. Goldstein, I. Woolley, J. Collett, 1997, Australian and New Zealand journal of medicine.

C-reactive protein is a prognostic biomarker in pancreatic ductal adenocarcinoma patients.

J. Kench, V. Gebski, N. Waddell, 2023, Asia-Pacific journal of clinical oncology.

Oxaliplatin-induced haematological toxicity and splenomegaly in mice

D. Goldstein, J. Lees, Preet G S Makker, 2020, PloS one.

Development of a nomogram to predict overall survival in patients with locally advanced or metastatic gastrointestinal stromal tumor receiving first-line treatment with imatinib.

D. Goldstein, G. McArthur, D. Yip, 2010 .

Concordance between independent and investigator assessment of disease-free survival (DFS) in the APACT trial.

J. Reeves, J. Berlin, A. Biankin, 2020 .

A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer

D. Goldstein, J. Zhi, E. Chen, 2011, Cancer Chemotherapy and Pharmacology.

Updated survival from a randomized phase III trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas.

W. Scheithauer, J. Tabernero, V. Heinemann, 2014 .

TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer

V. Gebski, D. Goldstein, J. Zalcberg, 2016, Cancer Chemotherapy and Pharmacology.

Utilizing natural activity to dissect the pathophysiology of acute oxaliplatin-induced neuropathy

M. Friedlander, D. Goldstein, M. Kiernan, 2011, Experimental Neurology.

Oxaliplatin and Axonal Na+ Channel Function In vivo

M. Friedlander, D. Goldstein, M. Kiernan, 2006, Clinical Cancer Research.

1466P Napabucasin + nab-paclitaxel with gemcitabine in patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC): Results from the phase III CanStem111P study

M. Reni, J. Tabernero, T. Bekaii-Saab, 2021, Annals of Oncology.

Phase II study of vinflunine in patients with metastatic renal cell carcinoma

D. Goldstein, I. Davis, S. Ackland, 2006, Investigational New Drugs.

Interferon-alpha promotes the anti-proliferative effect of gefitinib (ZD 1839) on human colon cancer cell lines.

D. Goldstein, P. Russell, Jia-Lin Yang, 2005, Oncology.

LBA-1 Phase 3 APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + Gem) vs gemcitabine (Gem) alone in patients with resected pancreatic cancer (PC): Updated 5-year overall survival

J. Berlin, A. Biankin, P. Philip, 2021, Annals of Oncology.

INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)

V. Gebski, N. Pavlakis, Y. Bang, 2023, BMC Cancer.

Antitumor effect of somatostatin analogs in neuroendocrine tumors.

D. Goldstein, J. Zalcberg, R. Hicks, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

M. Büchler, J. Mackey, W. Greenhalf, 2018, British Journal of Cancer.

Management of metastatic renal cell carcinoma in the era of targeted therapies.

D. Goldstein, K. Webber, D. Yip, 2011 .

Adding irinotecan to first-line gemcitabine improves tumour response in advanced pancreatic cancer.

D. Goldstein, D. Yip, 2005, Cancer treatment reviews.

Prognosis model for overall survival in locally advanced unresecable pancreatic carcinoma: An ancillary study of the LAP 07 trial.

M. Moore, D. Goldstein, D. Vernerey, 2015 .

Selective Internal Radiation Therapy (SIRT) plus systemic chemotherapy with Irinotecan. A phase I dose escalation study

N. Pavlakis, D. Goldstein, I. Olver, 2005 .

Pharmacogenetic factors predicting the need for a higher dose of imatinib.

J. Schellens, D. Goldstein, R. Mathijssen, 2010 .

Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected].

V. Gebski, D. Goldstein, J. Zalcberg, 2011, European journal of cancer.

D. Goldstein, J. Zalcberg, D. Joseph, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapy‐induced peripheral neurotoxicity: A critical analysis

M. Koltzenburg, M. Friedlander, D. Goldstein, 2013, CA: a cancer journal for clinicians.

D. Goldstein, O. Bouché, F. Bonnetain, 2016, JAMA.

Immune-mediated processes implicated in chemotherapy-induced peripheral neuropathy.

D. Goldstein, Susanna B. Park, J. Lees, 2017, European journal of cancer.

D. Goldstein, J. Bridgewater, A. Lohse, 2015, BMC Cancer.

EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma.

M. Stockler, N. Pavlakis, D. Goldstein, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Oncotargets and Therapy Dovepress Next-generation Egfr/her Tyrosine Kinase Inhibitors for the Treatment of Patients with Non- Small-cell Lung Cancer Harboring Egfr Mutations: a Review of the Evidence

D. Goldstein, Jia-Lin Yang, P. Crowe, 2022 .

D. Goldstein, C. Kaiser, V. Gorbounova, 2008, Oncology.

CA19-9 decrease at 8 weeks as a predictor of overall survival (OS) in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients with metastatic pancreatic cancer (MPC).

J. Tabernero, D. Goldstein, J. Infante, 2013 .

nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.

W. Scheithauer, J. Tabernero, V. Heinemann, 2015, Journal of the National Cancer Institute.

620PDYOSEMITE: A 3 arm double-blind randomized phase 2 study of gemcitabine, paclitaxel protein-bound particles for injectable suspension, and placebo (GAP) versus gemcitabine, paclitaxel protein-bound particles for injectable suspension and either 1 or 2 truncated courses of demcizumab (GAD)

T. Kolevska, M. Hidalgo, D. Goldstein, 2017 .

CanStem111P trial: A phase III study of napabucasin plus nab-paclitaxel (nab-PTX) with gemcitabine (gem) in adult patients with metastatic pancreatic adenocarcinoma (mPDAC).

M. Reni, E. Van Cutsem, J. Tabernero, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study.

Robin L. Jones, J. Blay, Yoon-Koo Kang, 2023, European Journal of Cancer.